Company: OCEA
Filing Date: 2025-04-08
Form Type: 10-K
Source: 0001641172-25-003155
Chunk: 2200

Company: Ocean Biomedical, Inc.
Filing Date: 2025-04-08
Form: 10-K
Item: Item 1A
Chunk 2200
---
 adequate to cure the cancer or prolong life without a cure. Whenever first line therapy, usually chemotherapy, antibody
drugs, tumor-targeted small molecules, hormone therapy, radiation therapy, surgery, or a combination of these, proves unsuccessful, second
line therapy may be administered. Second line therapies often consist of more chemotherapy, radiation, antibody drugs, tumor-targeted
small molecules, or a combination of these. Third line therapies can include chemotherapy, antibody drugs and small molecule tumor-targeted
therapies, more invasive forms of surgery and new technologies. In our oncology program, we may initially seek approval of certain of
our product candidates as a second or third line therapy, for use in patients with relapsed or refractory metastatic cancer. Subsequently,
for those product candidates that prove to be sufficiently safe and beneficial, if any, we would expect to seek approval as a second
line therapy and potentially as a first line therapy, but there is no guarantee that our product candidates, even if approved as a second
or subsequent line of therapy, would be approved for an earlier line of therapy, and, prior to any such approvals, we may have to conduct
additional clinical trials.

89

Our
projections of both the number of people who have the cancers we are targeting, who may have their tumors genetically sequenced, as well
as the subset of people with these cancers in a position to receive a particular line of therapy and who have the potential to benefit
from treatment with our product candidates, are based on our beliefs and estimates. These estimates have been derived from a variety
of sources, including scientific literature, surveys of clinics, patient foundations or market research, and may prove to be incorrect.
Further, new therapies may change the estimated incidence or prevalence of the cancers that we are targeting. Consequently, even if our
product candidates are approved for a second or third line of therapy, the number of patients that may be eligible for treatment with
our product candidates may turn out to be much lower than expected. In addition, we have not yet conducted market research to determine
how treating physicians would expect to prescribe a product that is approved for multiple tumor types if there are different lines of
approved therapies for each such tumor type.

We
currently have no marketing and sales organization and have no experience as a company in commercializing products, and we may have to
invest significant resources to develop these capabilities. If we are unable to establish marketing and sales capabilities or enter into
agreements with third parties to market and